

AMENDMENTS TO THE SPECIFICATION

In the Specification

- 1.) Please insert the following paragraph on page 1, immediately following the title of the application, as follows:

PRIORITY CLAIM

This is the § 371 U.S. National Stage of International Application No.

PCT/US2004/037600, filed on November 10, 2004, which in turn claims the benefit of U.S.
Provisional Application No. 60/527,882, filed on December 4, 2003, which is incorporated
herein by reference in its entirety.

- 2.) Please amend the paragraph, beginning on page 3, line 15 of the specification as follows:

The present invention is also directed to an antibody or an antigen-binding fragment thereof, wherein said antibody comprises a variable heavy chain amino acid sequence of SEQ ID NO:78 and a variable light chain amino acid sequence of SEQ ID NO. 46, designated herein as the HuAIP12 T554I variant.

- 3.) Please amend the paragraph beginning on page 4, line 3 of the specification as follows:

Figure 2 depicts the inhibition of IP-10 mediated chemotaxis of BA/F3-CXCR3 cells by the HuAIP12 T554I variant antibody as compared to the original, unmodified HuAIP12 antibody.

- 4.) Please amend the paragraph beginning on page 9, line 3 of the specification as follows:

The amino acid sequence of the full-length wild-type human IP-10 is presented in SEQ ID NO: 1 (MNQTAILICC LIFLTLGQI GVPLSRTVRC TCISISNQPV NPRSLEKLEI IPASQFCPRV EIIATMKKG EKRCCLNPESK AIKNLLKAVS KERSKRSP). A “functionally active” IP-10 fragment or derivative exhibits one or more functional activities associated with the full-length, wild-type IP-10 protein, such as antigenic or immunogenic activity, ability to bind natural cellular substrates, such as its cognate receptor, etc. The functional activity of IP-10 proteins, derivatives and fragments can be assayed by various methods known to one skilled in the art (Coligan et al., eds., Current Protocols in Protein Science, John Wiley & Sons, Inc., Somerset, New Jersey (1998)). For purposes herein, functionally active fragments also include those fragments that comprise one or more structural domains of an IP-10 polypeptide, such as a binding domain. Protein domains can be identified using the PFAM program (Bateman A., et al., Nucleic Acids Res. 27: 260-2 (1999); <http://pfam.wustl.edu>).

5.) Please amend the paragraph beginning on page 15, line 25 of the specification as follows:

Anti-IP-10 fully human antibodies are also included in the present invention. In a preferred embodiment of the present invention, said fully human antibodies are isolated human antibodies and neutralize the activities of IP-10 described herein. HuAIP13 is an exemplification of humanized antibody that binds to IP-10. The amino acid sequences of the HuAIP13 heavy chain variable region and light chain variable region are SEQ ID No.:13 and 15, respectively. HuAIP12/HuAIP12 is another exemplification of humanized antibody that binds to IP-10. The amino acid sequences of the HuAIP12 heavy chain variable region and light chain variable region are SEQ ID No.:45 and 46, respectively.

6.) Please amend the paragraph beginning on page 34, line 1 of the specification as follows:

The resulting V gene fragments were cloned into the mammalian expression vectors pHuCkappa.rgpt.dE and pVg1.D.Tt (described, *supra*), and then combined to generate a single

expression vector for co-expression of the light and heavy chains. The DNA sequences of the humanized VL and VH mini-exons are depicted in SEQ ID Nos: 17 and 19, respectively, and deduced amino acid sequences λ of the humanized VL and VH mini-exons ~~are depicted~~ are depicted in SEQ ID Nos: 18 and 20, respectively.